Prediction: These 2 Stocks Will Join Nvidia, Meta, Apple, Amazon, and Microsoft in the Trillion-Dollar Club by 2030
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Novo Nordisk to invest $158 million in insulin plant in Brazil
Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Texas lawsuit alleges conspiracy to inflate insulin prices, seeks restitution
AUSTIN — Attorney General Ken Paxton sued major pharmaceutical makers and other companies Thursday, alleging they violated ...
Texas attorney general sues insulin makers and pharmacy middlemen over high costs
The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of ...
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...
Novo Nordisk has mitigation plans to minimize disruption from port strikes
Danish drugmaker Novo Nordisk said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its ...
Exclusive-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show
One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years ...
This IPO Biotech Stock Could Be the Next Eli Lilly
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.
Novo Nordisk's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.